Oragenics (OGEN) Income from Continuing Operations (2010 - 2026)
Oragenics' (OGEN) quarterly Income from Continuing Operations came in at 2201243.0 in Q1 2026, up 0.71% YoY from 2185715.2 in Q1 2025, and up 8.99% on a QoQ basis from 2418664.0 in Q4 2025.
Oragenics (OGEN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Income from Continuing Operations data on file, last reported at 2201243.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 0.71% year-over-year to 2201243.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9952296.0 (up 3.95% YoY) and the FY2025 annual result came in at 9862176.0, up 6.93% from the prior year.
- Income from Continuing Operations grew to 2201243.0 in Q1 2026, from 2418664.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2012885.0 in Q3 2023 to a low of 12747429.0 in Q4 2023.
- A 5-year average of 3394608.94 and a median of 2462870.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 469.66% — and 2024, when it surged 73.52%.
- Tracing OGEN's Income from Continuing Operations over 5 years: stood at 2237740.0 in 2022, then slumped by 469.66% to 12747429.0 in 2023, then surged by 73.52% to 3376144.0 in 2024, then increased by 28.36% to 2418664.0 in 2025, then grew by 8.99% to 2201243.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2201243.0 (Q1 2026), 2418664.0 (Q4 2025), and 3062670.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | -2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.53 Mn |
| Mar 31, 2026 | -2.20 Mn |
| Dec 31, 2025 | -2.42 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.22 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.45 Mn |
| Dec 31, 2023 | -12.75 Mn |
| Sep 30, 2023 | -2.01 Mn |
| Jun 30, 2023 | -3.05 Mn |
| Mar 31, 2023 | -2.84 Mn |
| Dec 31, 2022 | -2.24 Mn |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -3.59 Mn |
| Mar 31, 2022 | -4.59 Mn |
| Dec 31, 2021 | -2.29 Mn |
| Sep 30, 2021 | -4.38 Mn |